NCT07044947

Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）

Non-interventional Real-World Study of Oteseconazole in the Treatment of Vulvovaginal Candidiasis

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 3,000 (estimated)
• Sponsor: Beijing Tsinghua Chang Gung Hospital · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Oteseconazole is a novel, oral, highly selective inhibitor of fungal CYP51. Oteseconazole showed statistically significant and clinically meaningful treatment of severe VVC and was generally tolerated. The trial is a national multi-center, non-interventional observational real-world study, aiming to evaluate the effecacy and safety of oteseconazole in the treatment of patients with VVC. This study will include patients with severe vulvovaginal candidiasis (SVVC) . It is divided into prospective and retrospective parts.

Conditions

• Vulvovaginal Candidiasis

Interventions

Type	Name	Description
DRUG	Oteseconazole (VT-1161) 150mg capsule	Subjects with SVVC will be treated by Oteseconazole with 600 mg (150 mg per capsule) on D1, 450 mg on D2

Timeline

• Start date: 2025-08-10
• Primary completion: 2027-08-10
• Completion: 2030-08-10
• First posted: 2025-07-01
• Last updated: 2025-07-01